Antibiotics — Penicillins and Cephalosporins

• Penicillin-Binding Proteins (PBPs) Inhibition: Penicillins and cephalosporins covalently bind to penicillin-binding proteins (transpeptidases and carboxypeptidases), enzymes essential for cross-linking D-alanyl-D-alanine residues within the peptidoglycan layer via formation of peptide bridges. By acetylating the active site serine of these enzymes, β-lactams irreversibly prevent transpeptidation reactions, resulting in incomplete peptidoglycan maturation. This weakens the cell wall architecture, leading to osmotic instability, rupture, and bactericidal cell death—distinguishing these drugs from bacteriostatic agents. Different bacterial species and individual PBPs have varying affinities for different β-lactams, explaining differential spectrum coverage (e.g., penicillin G excellent for Streptococcus pyogenes, poor for gram-negatives due to limited PBP binding).

• Bacterial Cell Wall Architecture and Gram Classification: Gram-positive bacteria possess a thick peptidoglycan layer (20-30 nm) with few porins, allowing penicillins ready access to PBPs and explaining high susceptibility to penicillin G and aminopenicillins. Gram-negative bacteria have a thinner peptidoglycan layer (5-10 nm) surrounded by an outer lipid membrane containing porins; penicillin G penetrates poorly through these porins, while later-generation cephalosporins (especially cephalosporin generation 3-4) contain hydrophilic side chains facilitating porin transit and achieving superior gram-negative penetration. Anaerobes, including Bacteroides fragilis, typically possess few porins and express multiple β-lactamases, explaining variable susceptibility to different agents.

• β-Lactamase-Mediated Resistance: The most common mechanism of β-lactam resistance involves bacterial β-lactamases (penicillinases and cephalosporinases), serine hydrolases that cleave the critical β-lactam ring between the nitrogen and carbonyl carbon atoms, yielding microbiologically inactive penicilloic acid. Over 2,000 distinct β-lactamases have been characterized and classified by Ambler classification (Classes A-D); Class A enzymes (TEM-1, SHV-1, CTX-M) are inhibited by clavulanic acid and sulbactam, while Class C (AmpC) and Class D (oxacillinases) show variable inhibition. The prevalence of β-lactamase production explains why ampicillin is no longer used empirically for Escherichia coli, Haemophilus influenzae, and many Enterobacteriaceae, despite historical susceptibility. Extended-spectrum β-lactamases (ESBLs) hydrolyze third-generation cephalosporins, necessitating carbapenem therapy.

• Altered Penicillin-Binding Proteins (Altered PBPs): Resistance-conferring mutations in genes encoding PBPs (particularly in Streptococcus pneumoniae and Neisseria gonorrhoeae) reduce β-lactam binding affinity without eliminating function, resulting in reduced susceptibility rather than resistance. In S. pneumoniae, penicillin non-susceptibility (MIC 0.06-1 μg/mL) requires higher dosing or alternative agents; penicillin-resistant strains (MIC ≥2 μg/mL) typically require cephalosporin therapy or alternative agents. Multiple PBP mutations accumulate gradually, explaining the clinical observation that resistance emerges through prolonged selective pressure rather than single-step mutations.

• **Methicillin-Resistant Staphylococcus aureus (MRSA) and mecA Gene: MRSA strains possess the mecA gene** (typically on a staphylococcal cassette chromosome, SCC*mec*), encoding PBP 2a, a transpeptidase with extremely low affinity for all β-lactams including cephalosporins. This altered PBP allows continued cell wall synthesis even at high β-lactam concentrations. Clinical implications include cross-resistance to all penicillins and all cephalosporins; vancomycin or linezolid therapy becomes necessary. MRSA prevalence varies geographically and by healthcare setting (10-60% of S. aureus isolates in US hospitals), making empiric MRSA coverage essential in certain contexts (ICU, severe skin/soft tissue infections, recent hospitalization).

• Inoculum Effect and Time-Dependent Killing: Penicillins and cephalosporins exhibit time-dependent bactericidal activity, meaning bacterial kill depends on the duration of drug exposure above the minimum bactericidal concentration (MBC) rather than the peak concentration. Optimal dosing regimens maintain therapeutic drug levels throughout the dosing interval; prolonged infusions (e.g., infusing piperacillin-tazobactam over 4 hours rather than 30 minutes) improve pharmacodynamic target attainment and outcomes in critically ill patients. The inoculum effect describes reduced antibiotic efficacy with higher bacterial burden; this is particularly relevant in abscesses or endocarditis and may explain clinical failures despite in vitro susceptibility.

• Physiological Basis for Spectrum Variation: Penicillins G and V exhibit narrow spectrum limited to gram-positive cocci and anaerobes due to poor gram-negative penetration and vulnerability to gram-negative β-lactamases. Aminopenicillins (ampicillin, amoxicillin) gained modest gram-negative activity through enhanced porin penetration but remain inactivated by common β-lactamases. Extended-spectrum penicillins (piperacillin, azlocillin) achieve broader gram-negative coverage including Pseudomonas aeruginosa through additional structural modifications improving porin interaction. First-generation cephalosporins resemble penicillins in spectrum; second-generation agents add some gram-negative coverage at the expense of reduced gram-positive and anaerobic activity; third-generation agents achieve significant gram-negative penetration (including gram-negative anaerobes and some Pseudomonas); fourth-generation agents combine third-generation gram-negative coverage with restored gram-positive activity.

• Organism Identification and β-Lactamase Production Status: Successful penicillin/cephalosporin therapy depends fundamentally on accurate organism identification and determination of β-lactamase production via standard susceptibility testing. β-Lactamase-producing strains of H. influenzae, Moraxella catarrhalis, and anaerobes require β-lactamase–inhibitor combinations or later-generation agents. For Staphylococcus aureus, differentiation between methicillin-susceptible (MSSA) and MRSA strains is critical; MSSA strains respond to penicillinase-resistant penicillins (nafcillin, oxacillin) or first-generation cephalosporins, while MRSA requires alternative agents entirely.

• Geographic and Healthcare Setting-Specific Resistance Patterns: The prevalence of resistance varies significantly by geographic region, institution, and patient population. MRSA colonization rates exceed 30% in some ICUs but remain <5% in others; extended-spectrum β-lactamase (ESBL)–producing gram-negative organisms predominate in certain regions (Southeast Asia, Middle East), influencing empiric therapy. Local antibiogram data (periodic institutional reports of antibiotic susceptibility patterns) should guide empiric therapy selection, as empiric ampicillin is inappropriate in regions with >30% ampicillin-resistant E. coli.

• Host Factors Influencing Pharmacokinetics and Outcomes: Renal function critically determines dosing of renally excreted penicillins and cephalosporins; severe renal impairment (glomerular filtration rate <30 mL/min) necessitates dose reduction to prevent toxic accumulation. Obesity and pregnancy (expanded drug clearance) require dose escalation. ICU patients often demonstrate altered pharmacokinetics (increased volume of distribution, variable renal clearance) necessitating higher or more frequent dosing and TDM (therapeutic drug monitoring) for optimal target attainment.

• Allergy History and Cross-Reactivity Risk: True IgE-mediated penicillin allergy (urticaria, angioedema, anaphylaxis) increases risk of cephalosporin allergy; however, cross-reactivity is approximately 1-3% for third-generation cephalosporins (much lower than historical estimates of 10-15%), permitting cautious use of cephalosporins in penicillin-allergic patients with careful documentation and monitoring. Ampicillin rash, a maculopapular rash often occurring with concurrent Epstein-Barr virus or Cytomegalovirus infection (not true allergy), does not contraindicate future penicillin use.

• Concomitant Medication and Disease Interactions: Methotrexate clearance may be reduced by high-dose penicillins, increasing toxicity risk. Oral contraceptive efficacy may be reduced (though evidence is limited) with broad-spectrum antibiotics through gut flora disruption and reduced enterohepatic recirculation of ethinyl estradiol. Probenecid inhibits renal tubular secretion of penicillins and cephalosporins, elevating drug levels; this was historically used to prolong antibiotic effect but is rarely employed in modern practice.

• Acute Bacterial Infections Responsive to Penicillins: Streptococcal pharyngitis (caused by Streptococcus pyogenes) presents classically with sore throat, fever, exudate, and cervical lymphadenopathy; penicillin G or amoxicillin represents ideal therapy. Pneumococcal pneumonia typically presents with acute fever, productive cough with rusty-colored sputum, pleuritic chest pain, and focal consolidation on chest imaging; penicillin or cephalosporin selection depends on susceptibility, with high-dose penicillin effective for susceptible strains and cephalosporin preferred for non-susceptible strains. Bacterial meningitis caused by susceptible gram-positive cocci (predominantly Streptococcus pneumoniae in adults and children >2 months) presents with the classic meningeal triad of fever, headache, and nuchal rigidity; high-dose third-generation cephalosporin (ceftriaxone 2g IV Q12H) achieves adequate CSF penetration superior to penicillin and must be administered emergently given mortality >50% with delayed treatment.

• Gram-Negative Infections Requiring Extended-Spectrum Agents: Community-acquired pneumonia involving gram-negatives (Klebsiella, E. coli, Haemophilus) or healthcare-associated pneumonia requires second- or third-generation cephalosporins or extended-spectrum penicillins (piperacillin-tazobactam). Urinary tract infections from ESBL-producing organisms necessitate cephalosporin therapy, as trimethoprim-sulfamethoxazole and fluoroquinolones may demonstrate in vitro resistance. Intra-abdominal infections (perforated viscus, peritonitis) require coverage of gram-positive, gram-negative, and anaerobic organisms; piperacillin-tazobactam or cephalosporin with anaerobic coverage (cefoxitin) become necessary.

• Anaerobic Infections and Special Considerations: Anaerobic bacterial infections (aspiration pneumonia, intra-abdominal abscesses, diabetic foot infections) frequently involve mixed flora including Bacteroides fragilis, Peptostreptococcus, and other obligate anaerobes. Penicillin G alone, despite historical use, is inadequate for Bacteroides coverage; penicillin plus β-lactamase inhibitor (ampicillin-sulbactam), extended-spectrum penicillin with inhibitor (piperacillin-tazobactam), or second-generation cephalosporin (cefoxitin) become necessary. The clinical presentation of severe pneumonia with pleurisy or abscess formation weeks after aspiration strongly suggests anaerobic involvement.

• Acute Allergic Manifestations (Drug Reactions Rather Than Infection): Penicillin-induced urticaria presents with diffuse pruritic rash 1-3 days after initiation; this represents true IgE-mediated hypersensitivity and mandates immediate drug discontinuation and future avoidance. Anaphylaxis, characterized by acute onset of hypotension, bronchospasm, and airway edema minutes to hours after administration, represents life-threatening type I hypersensitivity requiring immediate epinephrine administration and ICU monitoring. Ampicillin rash, a characteristic maculopapular exanthem occurring during treatment of Epstein-Barr virus infection (mononucleosis), does not represent true allergy and does not contraindicate future penicillin use.

• Delayed Hypersensitivity Reactions: Serum sickness–like reactions present 7-10 days after penicillin initiation with fever, arthralgias, lymphadenopathy, and rash; this represents type III immune complex-mediated hypersensitivity and requires drug discontinuation but does not necessarily preclude future cephalosporin use (cross-reactivity risk ~1-3%). Stevens-Johnson syndrome and toxic epidermal necrolysis, rare but potentially fatal reactions involving massive epidermal sloughing (>30% body surface area in TEN), can be triggered by cephalosporins and require immediate discontinuation, supportive care in burn units, and avoidance of future β-lactam exposure.

• Organ-Specific Toxicity and Adverse Effects: Seizures, particularly with high-dose cephalosporins or penicillins in patients with renal impairment, result from CNS accumulation of drug causing direct neurotoxicity and GABA antagonism; elderly patients and those with chronic kidney disease face elevated risk. Acute interstitial nephritis, manifesting as acute rise in serum creatinine 7-10 days after initiation, represents drug-induced T-cell–mediated hypersensitivity; this reversible complication requires drug discontinuation but does not necessarily preclude future use of alternative β-lactams.

• Organism Identification via Culture and Gram Stain: Gram stain of clinical specimens (sputum, CSF, urine, wound exudate) provides rapid morphologic information (gram-positive cocci in clusters suggest S. aureus; in chains suggest Streptococcus species; gram-negative rods suggest enteric or other gram-negative organisms) within 15-30 minutes. Bacterial culture on selective and enriched media represents the gold standard, taking 24-48 hours for preliminary identification and 48-72 hours for complete susceptibility testing.

Hypersensitivity (the dominant toxicity)

• Type I (IgE-mediated): the β-lactam ring opens and haptenizes host proteins (benzylpenicilloyl = major determinant), generating IgE that cross-links mast cell FcεRI. Urticaria, bronchospasm, angioedema, hypotension within minutes to an hour. Treatment is epinephrine 0.3 mg IM to the anterolateral thigh first (AAAAI/ACAAI anaphylaxis parameter) — antihistamines and steroids are adjuncts, never the initial step.
• Type II: hapten-coated RBCs → Coombs-positive hemolytic anemia, classically with high-dose penicillin G and ceftriaxone; also neutropenia and platelet dysfunction with prolonged high-dose therapy.
• Type III: serum sickness–like reaction at 7–14 days (fever, arthralgia, rash), most often cefaclor and amoxicillin in children.
• Type IV: delayed maculopapular exanthem, DRESS, SJS/TEN, and acute interstitial nephritis (T-cell mediated; classically methicillin, also nafcillin) with rising creatinine, sterile pyuria, WBC casts, and eosinophilia. Stop the drug; steroids are used but evidence is limited.
• Amoxicillin/ampicillin rash during EBV mononucleosis is not IgE-mediated and does not label the patient allergic.

Non-immune toxicities

• Neurotoxicity: β-lactams antagonize GABA-A; high doses with renal impairment cause myoclonus, encephalopathy, nonconvulsive status. Cefepime is the classic offender; imipenem is the highest-risk carbapenem. Prevention is renal dose adjustment.
• C. difficile colitis: broad-spectrum cephalosporins and ampicillin are top precipitants; treat with oral vancomycin or fidaxomicin per IDSA/SHEA.
• NMTT side-chain agents (cefotetan, cefamandole, cefoperazone): hypoprothrombinemia (reversed with vitamin K) and a disulfiram-like reaction with alcohol.
• Ceftriaxone: biliary sludging/pseudolithiasis; contraindicated in neonates with hyperbilirubinemia and in any neonate receiving calcium-containing IV fluids (precipitation) — use cefotaxime (AAP Red Book).
• Hepatic: cholestatic injury with amoxicillin-clavulanate; oxacillin hepatitis; nafcillin extravasation causes tissue necrosis.

• Anaphylaxis is a clinical diagnosis and epinephrine is the single best next step: epinephrine 0.3 mg IM, then airway support and IV fluids. Distractors that examiners plant: diphenhydramine, methylprednisolone, or "send tryptase" — none come first.
• Ampicillin + EBV mononucleosis = nonallergic morbilliform rash: the vignette gives a teenager with pharyngitis, posterior cervical nodes, splenomegaly, and atypical lymphocytes. Do not label penicillin allergy and do not switch to vancomycin.
• Cephalosporins miss LAME organisms: Listeria, Atypicals, MRSA, Enterococci. This is why IDSA meningitis guidance adds ampicillin to ceftriaxone plus vancomycin in patients over 50 or immunocompromised — Listeria coverage.
• MRSA resistance is mecA → PBP2a, an altered transpeptidase with negligible β-lactam affinity, so every penicillin and every cephalosporin fails. The one exception tested is ceftaroline, the anti-MRSA cephalosporin.
• For MSSA bacteremia, use an antistaphylococcal β-lactam (nafcillin, oxacillin, or cefazolin), not vancomycin — vancomycin is inferior for MSSA despite in vitro susceptibility.
• Penicillin allergy cross-reactivity with cephalosporins is roughly 1–3%, driven by shared R1 side chains, not the β-lactam ring; cefazolin has a unique side chain and is generally safe. The 10% figure is obsolete, and most "allergic" patients de-label after evaluation (AAAAI/ACAAI drug allergy parameter).
• Penicillin is the only acceptable therapy for syphilis in pregnancy: if the patient reports allergy, desensitize and treat (CDC STI Treatment Guidelines) — doxycycline is contraindicated and the classic wrong answer. Expect Jarisch-Herxheimer fever hours after the first dose.
• Encephalopathy or myoclonus in a patient with CKD on cefepime is drug neurotoxicity from GABA-A antagonism, not sepsis-related delirium — the fix is dose adjustment or discontinuation, not escalation of antibiotics.